Article Text

PDF
GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
  1. William Tillett1,2,
  2. Ana-Maria Orbai3,
  3. Alexis Ogdie4,
  4. Ying Ying Leung5,
  5. Vibeke Strand6,
  6. Dafna D Gladman7,
  7. Philip J Mease8,
  8. Laura C Coates9
  9. On Behalf of the GRAPPA OMERACT Psoriatic Arthritis working group
  1. 1Royal National Hospital for Rheumatic Disease, Bath, UK
  2. 2Pharmacy and Pharmacology, University of Bath, Bath, UK
  3. 3Department of Medicine/Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
  4. 4Division of Rheumatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  5. 5Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
  6. 6Department of Immunology/Rheumatology, Stanford University, Stanford, California, USA
  7. 7Krembil Research Institute, University Health Network,Toronto Western Hospital, Toronto, Ontario, Canada
  8. 8Department of Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA
  9. 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  1. Correspondence to Dr William Tillett, Royal National Hospital for Rheumatic Disease, University of Bath, BA11RL, Bath, UK; w.tillett{at}nhs.net

Statistics from Altmetric.com

We read with interest the recent letter by Ramiro et al1 reporting data from a systematic literature review on the measurement of enthesitis, dactylitis and nail disease in psoriatic arthritis (PsA) clinical trials. The authors highlight the great variety in the outcome measures chosen, cut points and the statistical analysis performed (percentage change, proportion resolved). We are pleased the authors have highlighted this problem and agree with their viewpoints on the clear lack of standardisation of domains and instruments in clinical trials evidenced by the data. Indeed this inconsistency of data reporting has led to significant heterogeneity in both physician-assessed and patient-reported outcomes particularly in the field of PsA. It is the domains of enthesitis, dactylitis, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles